VJHemOnc is committed to improving our service to you

SOHO 2020 | Long-term outcomes of anti-CD19 CAR-T in R/R CLL

VJHemOnc is committed to improving our service to you

David L. Porter

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the long-term outcomes from a Phase II, randomized dose optimization study of CAR-modified T-cells in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter